Disc Medicine reports RESTORE-PV Phase 2 results
Disc Medicine (IRON) reported Phase 2 RESTORE-PV DISC-3405 results, including a decline in mean phlebotomies and a share of patients phlebotomy-free at 26 weeks. Wedbush kept its $100 price target and unchanged stance.